US Broker Ratings

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Gem with 82% Potential Upside

In the evolving landscape of biotechnology, Enliven Therapeutics, Inc. (NASDAQ: ELVN), a clinical-stage biopharmaceutical company, is capturing investor attention with its promising pipeline and significant upside potential. With a market..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Unveiling a 68.97% Potential Upside in the Medical Device Sector

As investors navigate the ever-evolving landscape of healthcare, Treace Medical Concepts, Inc. (NASDAQ: TMCI) presents a noteworthy opportunity within the medical device sector. With a focus on innovative solutions for..

Arbutus Biopharma (ABUS) Stock Analysis: Exploring a Potential 64.89% Upside in the Biotechnology Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS), a clinical-stage biopharmaceutical company, has caught the attention of investors with its promising product pipeline targeting infectious diseases, particularly chronic Hepatitis B. With a market..

GH Research PLC (GHRS) Stock Analysis: Exploring a 128.73% Upside Potential in the Biotech Sector

GH Research PLC (NASDAQ: GHRS) is garnering significant attention in the biotech investment community, especially with its potential upside of 128.73% as highlighted by analysts. This Dublin-based clinical-stage biopharmaceutical company..

CeriBell, Inc. (CBLL) Stock Analysis: A 100% Potential Upside in the Medical Devices Sector

CeriBell, Inc. (NASDAQ: CBLL), a healthcare company specializing in medical devices, has been gaining attention due to its innovative approach to diagnosing and managing serious neurological conditions. Headquartered in Sunnyvale,..

Altimmune, Inc. (ALT): Investor Outlook Highlights a Stunning 328% Potential Upside

Altimmune, Inc. (NASDAQ: ALT) is garnering significant attention in the biotechnology sector, where its focus on groundbreaking treatments for obesity, metabolic, and liver diseases positions it as a potentially transformative..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Navigating the 2.29% Potential Upside in Biotechnology

Fortrea Holdings Inc. (FTRE), a prominent player in the healthcare sector and a provider of biopharmaceutical product development solutions, has caught the attention of investors who are keen to explore..

Akebia Therapeutics, Inc. (AKBA): Investor Outlook with a Compelling 92.71% Potential Upside

Investors with an eye on the healthcare sector have likely come across Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company with a promising portfolio aimed at addressing kidney diseases. With..

Anavex Life Sciences Corp. (AVXL): Investor Outlook Reveals 169% Upside Potential

Anavex Life Sciences Corp. (NASDAQ: AVXL), a prominent player in the biotechnology sector, is drawing significant attention from investors, particularly due to its promising pipeline of drugs aimed at treating..

Semler Scientific, Inc. (SMLR) Stock Analysis: Exploring a Potential 151.99% Upside

Semler Scientific, Inc. (NASDAQ: SMLR), a player in the healthcare sector specializing in medical devices, is capturing investor attention with a potential upside of 151.99%. This intriguing figure stems from..

Valneva SE (VALN) Stock Analysis: Exploring a Potential 78% Upside in the Biotechnology Sector

Valneva SE (NASDAQ: VALN), a specialty vaccine company based in France, is making waves in the biotechnology sector with a promising portfolio of prophylactic vaccines for infectious diseases that have..

SIGA Technologies Inc. (SIGA) Stock Analysis: Examining the Healthcare Player with a Strong Forward P/E of 4.18

SIGA Technologies Inc. (NASDAQ: SIGA), a prominent player in the healthcare sector, is catching the eye of investors with its compelling forward price-to-earnings (P/E) ratio of 4.18, indicating potential undervaluation..

AxoGen, Inc. (AXGN) Investor Outlook: Assessing the 83.84% Upside in the Peripheral Nerve Repair Market

AxoGen, Inc. (AXGN), a leader in the healthcare sector’s medical devices industry, is gaining investor attention due to its robust potential upside. With an impressive 83.84% potential upside based on..

Tectonic Therapeutic, Inc. (TECX) Stock Analysis: Unveiling a Potential 257.78% Upside

Tectonic Therapeutic, Inc. (NASDAQ: TECX), a promising player in the biotechnology sector, is capturing the attention of investors with its remarkable potential upside of 257.78%. This Massachusetts-based company is at..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating a 31.58% Potential Upside in Healthcare

InnovAge Holding Corp. (NASDAQ: INNV), a key player in the healthcare sector, offers a unique proposition for investors interested in the medical care facilities industry. With a market capitalization of..

Sionna Therapeutics, Inc. (SION): Investor Outlook with a 101.15% Potential Upside

Sionna Therapeutics, Inc. (NASDAQ: SION), a burgeoning player in the biotechnology sector, is capturing investors’ attention with a remarkable potential upside of 101.15%, as indicated by analyst ratings. Headquartered in..

AbCellera Biologics Inc. (ABCL) Stock Analysis: 67.90% Potential Upside Beckons Investors

AbCellera Biologics Inc. (NASDAQ: ABCL), a notable player in the biotechnology sector, has garnered significant attention from investors due to its impressive potential upside of 67.90%, as suggested by analyst..

REGENXBIO Inc. (RGNX) Stock Analysis: Navigating a Potential 244% Upside in the Biotech Sector

REGENXBIO Inc. (NASDAQ: RGNX), a clinical-stage biotechnology company, is capturing investor attention with its promising 244.10% potential upside. Specializing in gene therapies targeting genetic disorders, the firm is headquartered in..

Immunome, Inc. (IMNM) Stock Analysis: A Biotech with 117.97% Potential Upside

Immunome, Inc. (NASDAQ: IMNM), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative cancer therapies. Based in Bothell, Washington, Immunome focuses on developing targeted treatments..

Praxis Precision Medicines, Inc (PRAX)

⚠️ No article content returned.

..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds